Product Overview
Mobilized peripheral blood CD34+ hematopoietic stem and progenitor cells are positively selected using a immunomagnetic CD34 microbead labeling system. Cells are formulated in Lonza Fresh Media and shipped in a cryovial. Cell purity is determined using a FACS assay. Count and viability is determined using AO/PI. Cells are collected from healthy donors following IRB protocols.
Request More InfoStorage and Content
1 vial fresh cells, containing ≥ 1 million cellsSDS, CoA, and Instructions
Safety Data Sheets (SDS)
Choose a language to view the SDS.
Certificate of Analysis (CoA)
Please enter Lot Number, including all zeros, located on the product label and please take into account that it is case sensitive.
-
Instructions and Technical Sheet- Human CD34+ Cells
Educational Material
Brochures, White Papers etc.
Videos
-
Instructions and Technical Sheet- Human CD34+ Cells
-
CD34+ Cells for Cell and Gene Therapy Process Development
In this interview Dr. Manon Destalminil, Bioprocessing Project Leader at CellProthera, discusses the advantages of using research-grade CD34+ cells for cell and gene therapy process development. Please register to read.
-
Live-cell imaging of CD34+ cells with Nanolive’s 3D Cell Explorer
Human cord blood CD34+ stem/progenitor cells were cultured in X-VIVO™ 15 serum-free hematopoietic cell medium, in the presence of recombinant human thrombopoietin (25ng/mL), Rlt3 ligand (25ng/mL) and stem cell factor (13ng/mL). The culture was coated with fibronectin. Live cell imaging was performed with Nanolive’s 3D Cell Explorer for 15 hours (3 images/min during 15hours) and cell migration was captured.